Skip to main content

Paul Eckburg

Equibles does not estimate personal net worth.

About Paul Eckburg

AN2 Therapeutics, Inc. reported in an 8-K filed August 8, 2024 that Paul Eckburg was terminated as Chief Medical Officer, effective August 30, 2024. The proxy statement of AN2 Therapeutics, Inc. reports total compensation of $946,501 for Paul Eckburg in fiscal 2024, including a base salary of $325,500. Disclosed compensation is on record for 4 fiscal years.

“Paul Eckburg, M.D., the Company's Chief Medical Officer, will depart the Company effective as of August 30, 2024 (the "Transition Date").”
AN2 Therapeutics, Inc. Form 8-K, filed August 8, 2024 · Read the filing

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 AN2 Therapeutics, Inc. (ANTX) $325,500 $946,501
2023 AN2 Therapeutics, Inc. (ANTX) $465,000 $1,453,786
2022 AN2 Therapeutics, Inc. (ANTX) $427,399 $1,393,156
2021 AN2 Therapeutics, Inc. (ANTX) $258,125 $903,053

Recent activity